KalVista Pharmaceuticals Inc. has announced the acceptance of three abstracts for presentation at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, scheduled to take place in Philadelphia, Pennsylvania, from February 27 to March 2, 2026. The presentations will include data on EKTERLY® (sebetralstat), with two poster sessions scheduled for February 27 covering response drivers in sebetralstat placebo-controlled clinical trials and on-demand treatment patterns in the KONFIDENT-S study. An additional late-breaking poster on the management and burden of hereditary angioedema attacks will be presented on March 1. The results from these studies will be presented at the meeting, and links to all presentations will be made available on the KalVista website under Publications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalvista Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260212886266) on February 12, 2026, and is solely responsible for the information contained therein.